^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr amplification(9)(p24.1)

    almost5years
    Radio-Immunotherapy in MAlignant Lymphoma 1 (RIMAL1) Radio-Immunotherapie bij MAligne Lymfoom 1 (RIMAL1) (clinicaltrialsregister.eu)
    P4, N=20, Ongoing, Radboud University Medical Centre
    Clinical • New P4 trial • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    MET mutation • Chr amplification(9)(p24.1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)